Bristol-Myers Squibb employees cycle Coast to Coast to raise money and awareness for cancer research

Bristol-Myers Squibb Today, the first of six teams of Bristol-Myers Squibb Company (NYSE:BMY) oncology employees set out from Cannon Beach on the Oregon coast on the first leg of the 2016 Coast 2 Coast 4 Cancer Ride , a 21-day cycling ride that will bring together 80 riders to cover approximately 2,800 miles on a mission for cancer patients and their loved ones by raising money for Stand Up To Cancer's innovative cancer research programs.

As part of the 2016 Coast 2 Coast 4 Cancer Ride , Bristol-Myers Squibb will match funds raised dollar-for-dollar up to $500,000, to support Stand Up To Cancer, whose collaborative "Dream Teams" of scientific researchers are working together to accelerate cancer research and to provide new treatments to patients. Last year's ride raised $841,000 for Stand Up To Cancer research and this year the goal is even higher - the Coast 2 Coast 4 Cancer Ride aims to reach $1,000,000 in donations.

"I could not be prouder of these riders, many of whom spend the majority of their time in an office and not on a bike. But they are committed to doing whatever it takes to help patients fighting cancer because we all take this cause very personally," said Chris Boerner, PhD, president and head of U.S. commercial operations, Bristol-Myers Squibb. "Everyone on these teams is riding for someone they know who has been touched by cancer. This year, I’m riding for my late cousin, whose strength in fighting stomach cancer inspired me to dedicate my professional career to fighting cancer."

One of this year's riders, Lee Krug, MD, explained, "Like so many Coast 2 Coast 4 Cancer Ride team members, I have seen the devastating impact that cancer can have on patients and their loved ones, but also the strength and endurance that they so often show. They really are our inspiration on the road. This ride is about hope and about our combined efforts for patients."

"One in two men and one in three women in the U.S. will be affected by cancer, so we all have someone we can stand up for. For the third year in a row, the Coast 2 Coast 4 Cancer Ride is standing alongside us as we work to make every person diagnosed with cancer a survivor," said Katie Couric, Yahoo Global News anchor and Stand Up To Cancer co-founder. "You take these incredibly dedicated riders, and you combine them with Bristol-Myers Squibb's commitment to match money raised, dollar-for-dollar, up to $500,000, and what you have is a truly powerful, winning team. That's what patients fighting cancer deserve, and our hope is that everyone will join us in supporting the Coast 2 Coast 4 Cancer Ride effort."

For more information about this epic team effort and to follow the riders as they cross the country, visit cancerbikeride.org.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry's resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, Ph.D., conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...

Pfizer and BioNTech choose lead mRNA vaccine candi…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a singl...